0.95
+0.0236(+2.55%)
Currency In USD
Previous Close | 0.93 |
Open | 0.93 |
Day High | 0.98 |
Day Low | 0.93 |
52-Week High | 1.98 |
52-Week Low | 0.52 |
Volume | 3.25M |
Average Volume | 5.64M |
Market Cap | 277.43M |
PE | -4.75 |
EPS | -0.2 |
Moving Average 50 Days | 0.88 |
Moving Average 200 Days | 0.83 |
Change | 0.02 |
If you invested $1000 in Ocugen, Inc. (OCGN) 10 years ago, it would be worth $2.48 as of July 04, 2025 at a share price of $0.95. Whereas If you bought $1000 worth of Ocugen, Inc. (OCGN) shares 5 years ago, it would be worth $4,337.9 as of July 04, 2025 at a share price of $0.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
GlobeNewswire Inc.
Jun 23, 2025 11:30 AM GMT
Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseasesOrthoCellix is deve
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
GlobeNewswire Inc.
Jun 16, 2025 11:02 AM GMT
MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cl
Ocugen To Present at BIO International Convention 2025
GlobeNewswire Inc.
Jun 11, 2025 11:30 AM GMT
MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO Internati